Metformin, a decades-old diabetes medication, is emerging as a surprising contender in the fight against age-related vision loss. Recent research suggests it may help protect the aging retina and slow changes that eventually impair sight.
Age-related macular degeneration (AMD) and other retinal diseases are leading causes of irreversible blindness in older adults. As we age, oxidative stress, chronic inflammation, and abnormal blood vessel growth damage the delicate tissues at the back of the eye, especially the macula, which is critical for sharp central vision.
Current treatments can help in advanced stages, such as injections for “wet” AMD, but there are no widely available therapies that reliably prevent or halt early retinal aging. That gap has driven interest in repurposing safe, well-known drugs such as metformin.
Metformin: More Than a Diabetes Drug
Metformin is one of the most prescribed medications worldwide for type 2 diabetes, where it improves insulin sensitivity and lowers blood sugar. Over the last decade, it has also been studied for “anti-aging” benefits, including potential protection for the heart, brain, and eyes.
In the retina, preclinical work shows that metformin exerts anti-inflammatory, antioxidant, and antiangiogenic effects meaning it can reduce damaging inflammation, oxidative stress, and abnormal vessel growth. Animal and cell studies report that metformin helps preserve retinal structure, normalises key molecules like VEGF and inflammatory cytokines, and supports healthier retinal vasculature.
New Evidence: Metformin and Age-Related Vision Loss
A growing number of human studies are now backing up these lab findings. A recent five-year, image-based study in people with type 2 diabetes found that those taking metformin had about 37% lower odds of developing intermediate AMD compared with non-users, even after adjusting for other factors. This suggests metformin could help delay a critical stage of macular degeneration before major vision loss occurs.
Systematic reviews and meta-analyses pooling millions of participants also report that metformin use is associated with reduced odds of AMD overall. Additional observational work indicates that metformin may slow progression to both dry and wet forms of AMD and may also offer protection against other retinal diseases such as diabetic retinopathy and glaucoma.
Because metformin activates AMPK and influences cellular energy and autophagy pathways, researchers believe it may help retinal cells better manage waste products and resist stress over time.
(Liu et al., 2025) Metformin Improves Visual Cortex Information Processing. Aged mice (red) exhibit lower information processing than young mice (green), particularly with larger populations of neurons. However, aged mice treated with metformin (blue) exhibit even higher levels of information processing than young mice.
What This Means for Patients
Metformin is not yet an approved treatment for AMD or other age-related eye conditions, and experts emphasise that more randomised clinical trials are needed. Ongoing and planned studies are testing whether oral metformin can directly slow retinal degeneration in specific diseases such as ABCA4 retinopathy and geographic atrophy.
For now, the findings are encouraging but not a license for self-prescribing. Metformin can cause side effects and is typically used under medical supervision, especially in people without diabetes or with kidney issues.
If you are concerned about aging and vision:
Metformin’s track record, safety profile, and emerging retinal data make it one of the most promising drug candidates in the quest to slow age-related vision decline offering hope that future therapies may not only treat, but also delay, the onset of blinding eye diseases.
Dosage
Model: 12-month-old male C57BL/6J mice
Dosage: 250 mg/kg of metformin (corresponding to a human dose of 1200 mg/day) orally administered for three weeks
References
